November 2023 Newsletter
Crown Bioscience
We support drug discovery through translational research across oncology and immuno-oncology.
Welcome to the monthly Crown Bioscience newsletter. Discover some of our November highlights below to keep up to date with our recent developments, and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!
Expand your understanding of cutting-edge breakthroughs in oncology and immuno-oncology research with our latest scientific research from the SITC International Conference.
If you'd like to discuss your latest projects or how our services and technologies can support you, our team are ready to assist you. You can schedule a time to discuss any of our scientific posters at your convenience.
Which spatial transcriptomics technology platform will best align with your needs? Read our latest blog post, NanoString DSP vs. 10x Genomics Visium: A Comparative Study in Spatial Transcriptomics for Cancer Research, to gain valuable insights.
We’ve published our MuScreen 2024 schedule and the first registration deadline is coming up January 12th. MuScreen helps you rapidly identify the right markers and models for your preclinical programs improving efficiency and saving study time. Don't miss the 2024 schedule.
Evaluate your next generation therapeutics with the most clinically relevant models reflecting the patient population and cancer treatments of today. Our collection of 70+ clinically-aligned pretreated PDX models supports translational preclinical research for 30+ human cancer types.
Recommended by LinkedIn
Indivumed Services offers Multi-omics Grade Biospecimen that can help you excel in your research and development of personalized medicine. Read about these high-quality biospecimens, suitable for target identification, drug discover, biomarker exploration and validation.
Tumor organoids can serve as patient surrogates in high throughput drug screens and other in vitro applications, to reduce costs and time.
Our latest blog post highlights the value of using highly clinically relevant patient-relevant tumor organoids.
Accelerate preclinical oncology drug discovery by empowering your researchers with OrganoidXplore.
Our comprehensive factsheet outlines the key information on our large-scale organoid panel screening service to support your decision-making process.
Upcoming Events
© 2023 Crown Bioscience
Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States